Clinical Trials Logo

Clinical Trial Summary

This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for patients with locally advanced non-small cell lung cancer (LA-NSCLC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04951063
Study type Interventional
Source Sun Yat-sen University
Contact
Status Completed
Phase Phase 1
Start date June 1, 2021
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04726358 - ProCaLung: Project on Cancer of the Lung
Recruiting NCT06120803 - Esomeprazole and Radiation Induced Esophagitis Phase 2
Not yet recruiting NCT06448910 - The Efficacy and Safety of Cadonilimab (AK104) as Induction and Consolidation Therapy for Locally Advanced/Unresectable NSCLC Patients Receiving Concurrent Chemoradiotherapy Phase 2
Recruiting NCT06075524 - Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Recruiting NCT03735095 - Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer Phase 1/Phase 2
Recruiting NCT04680377 - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients